Australian Cardiovascular Alliance

Cardiovascular research benefiting all Australians

The Australian Cardiovascular Alliance (ACvA) is the peak leadership body in the country for the advancement of heart, stroke and vascular disease research.

It is a comprehensive collaboration of the very highest quality cardiovascular research bodies and scientific societies, individual researchers, industry and non-government organisations in Australia and is uniquely positioned to leverage key interactions between Australia’s strong research capability and the health system to improve health outcomes and reduce costs.

 

A Snapshot of Australia’s Cardiovascular Health

 

1 in 4 deaths in Australia are from CV disease, killing one Australian every 13 minutes.

 

At $10.4 billion annually, CV disease is Australia’s highest disease expenditure.

 

Atherosclerosis is the major underlying cause of CV disease and contributes significantly to heart attacks and strokes.

 

Heart failure will affect 20% of adults in their lifetime.

 

56,000 strokes in Australia in 2017; 65% of survivors are unable to carry out daily living activities unassisted.

 

One Australian limb lost every
2 hours due to complications of diabetes and peripheral arterial disease.

 

1.1 million hospitalisation for CV in 2016-17 accounting for 11% of all hospitalisation.

 

CVD disease disproportionately affects indigenous, remote and socioeconomically disadvantaged Australians.

As a member-based organisation, the ACvA believes the time is ripe for a new vision, new thinking and new strategies to solve cardiovascular disease.

We have developed a strong case for investment in cardiovascular health that represents a step change for cardiovascular health, bringing together our entire cardiovascular research community and promoting a whole-of-nation approach along a bi-directional translational pipeline. This will ensure that our talented researchers are aligned to the most urgent clinical challenges and that discoveries and innovative approaches to care are translated to the bedside in an accelerated manner. These ambitious objectives can only be met through significant investment, leadership and collaboration.

The ACvA brings expertise that spans fundamental biomedical research through to global clinical trial and public health bodies.

We work in partnership with the Heart Foundation, and industry members committed to the improvement of cardiovascular health in Australia. We are deeply engaged with the NHMRC-recognised Australian Health and Research Translational Centres and extend into primary care, which is essential for health impact.

ACvA Latest News

ACvA Latest Video

 

Winners from the Ozheart Song Contest!

ACvA Latest Tweets

Join us for tomorrow’s #ISHR webinar on cardiac regeneration, featuring Prof Masaki Ieda (Uni of Tsukuba) and A/Prof Rajesh Katare (Uni of Otago)!

@OzCvA @JMCCardiology @KimMellor_UAkl @PavlovicDavor @WACRAadvocate @QCVRN @HeartOtago https://twitter.com/k8weeks/status/1288619236982583296

Our new nanoparticle platform showing a lot of early promise for delivery in vivo. Congratulations @Santos_NanoTech & Joy, @DrRichardTan, @AHP_Chan - the product of a lot of hard work and persistence - and always great working with @thomasrcox. @ASBTE1 @CPC_usyd @OzCvA https://twitter.com/santos_nanotech/status/1290250299639128064

The University of Sydney has a Senior Project Officer position available to work alongside the CI of a newly funded NHMRC Synergy Grant known as SOLVE-CHD.

Find out more below: https://sydney.nga.net.au/cp/index.cfm?event=jobs.jati&returnToEvent=jobs.home&jobID=190A7DE0-45ED-4CED-94EC-ABF100ABD459&audienceTypeCode=EXT&UseAudienceTypeLanguage=1

Your thoughts @CVR_TomaszGuzik @josephahill @Duncanivison @garryjennings @KerryDo75584546 @euanashley @ProfSNicholls ?